From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.
作者信息
Yeh Ming-Lun, Yu Ming-Lung
机构信息
School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
出版信息
Clin Mol Hepatol. 2023 Oct;29(4):969-972. doi: 10.3350/cmh.2023.0359. Epub 2023 Sep 18.
Abstract
摘要
相似文献
1
From nonalcoholic steatohepatitis, metabolic dysfunction-associated fatty liver disease, to steatotic liver disease: Updates of nomenclature and impact on clinical trials.从非酒精性脂肪性肝炎、代谢功能障碍相关脂肪性肝病到脂肪性肝病：命名更新及其对临床试验的影响
Clin Mol Hepatol. 2023 Oct;29(4):969-972. doi: 10.3350/cmh.2023.0359. Epub 2023 Sep 18.
2
Impact of nomenclature as metabolic associated steatotic liver disease on steatotic liver disease prevalence and screening: a prospective population survey in Asians.代谢相关脂肪性肝病命名对脂肪性肝病患病率和筛查的影响：亚洲前瞻性人群调查。
J Gastroenterol Hepatol. 2024 Aug;39(8):1636-1647. doi: 10.1111/jgh.16554. Epub 2024 May 2.
3
Differences in the prevalence of NAFLD, MAFLD, and MASLD according to changes in the nomenclature in a health check-up using MRI-derived proton density fat fraction.根据 MRI 衍生质子密度脂肪分数在健康检查中命名法的变化，非酒精性脂肪性肝病、代谢相关脂肪性肝病和代谢相关脂肪性肝炎的患病率存在差异。
Abdom Radiol (NY). 2024 Sep;49(9):3036-3044. doi: 10.1007/s00261-024-04285-w. Epub 2024 Apr 8.
4
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.代谢功能障碍相关脂肪性肝病的批判性评价：两面性现代性的启示。
Clin Mol Hepatol. 2023 Oct;29(4):831-843. doi: 10.3350/cmh.2023.0277. Epub 2023 Aug 25.
5
Deciphering metabolic dysfunction-associated steatotic liver disease: insights from predictive modeling and clustering analysis.解析代谢相关脂肪性肝病：预测模型和聚类分析的新视角。
J Gastroenterol Hepatol. 2024 Jul;39(7):1382-1393. doi: 10.1111/jgh.16552. Epub 2024 Apr 17.
6
Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease.代谢相关脂肪性肝病：新命名对美国肝病研究学会非酒精性脂肪性肝病实践指南的影响及更新。
Hepatology. 2024 May 1;79(5):1212-1219. doi: 10.1097/HEP.0000000000000670. Epub 2023 Nov 9.
7
Liver and atherosclerotic risks of patients with cryptogenic steatotic liver disease.隐匿性脂肪性肝病患者的肝脏与动脉粥样硬化风险。
Hepatol Int. 2024 Jun;18(3):943-951. doi: 10.1007/s12072-023-10624-8. Epub 2024 Jan 16.
8
Fibrosis and steatotic liver disease in US adolescents according to the new nomenclature.美国青少年的纤维化和脂肪性肝病按新命名法分类。
J Pediatr Gastroenterol Nutr. 2024 Aug;79(2):229-237. doi: 10.1002/jpn3.12230. Epub 2024 May 1.
9
Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.慢性肾脏病发生时代谢功能障碍相关脂肪/脂肪变性肝病的严重程度和缓解情况。
J Am Heart Assoc. 2024 Mar 5;13(5):e032604. doi: 10.1161/JAHA.123.032604. Epub 2024 Feb 23.
10
Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.脂肪性肝病新命名法的意义及代谢相关脂肪性肝病的定义。
Aliment Pharmacol Ther. 2024 Jan;59(2):150-156. doi: 10.1111/apt.17846.
引用本文的文献
1
Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review.代谢功能障碍相关脂肪性肝炎相关肝细胞癌的发病机制与管理：一篇叙述性综述
Ewha Med J. 2024 Oct;47(4):e65. doi: 10.12771/emj.2024.e65. Epub 2024 Oct 31.
2
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes.线粒体mt12361A>G增加了非糖尿病患者中代谢功能障碍相关脂肪性肝病的风险。
World J Gastroenterol. 2025 Mar 14;31(10):103716. doi: 10.3748/wjg.v31.i10.103716.
3
Unlocking the potential of THR-β agonist therapies: resmetirom's chemistry, biology, and patent insights.释放THR-β激动剂疗法的潜力：雷司美托的化学、生物学及专利见解
Naunyn Schmiedebergs Arch Pharmacol. 2025 Aug;398(8):9703-9720. doi: 10.1007/s00210-025-03880-y. Epub 2025 Mar 11.
4
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD.双重病因性 MAFLD：乙型肝炎病毒、丙型肝炎病毒、酒精与 MAFLD 之间的相互作用。
Hepatol Int. 2024 Oct;18(Suppl 2):897-908. doi: 10.1007/s12072-024-10699-x. Epub 2024 Aug 8.
5
Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on "Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis".基于肠促胰岛素的疗法在代谢功能障碍相关脂肪性肝病（MASLD）管理中的应用：拼图中的一块：关于“胰高血糖素样肽-1受体激动剂与噻唑烷二酮类药物治疗非酒精性脂肪性肝病的比较：网状Meta分析”的社论
Clin Mol Hepatol. 2024 Oct;30(4):649-652. doi: 10.3350/cmh.2024.0558. Epub 2024 Jul 23.
6
TM7SF3 controls TEAD1 splicing to prevent MASH-induced liver fibrosis.TM7SF3 通过控制 TEAD1 的剪接预防 MASH 诱导的肝纤维化。
Cell Metab. 2024 May 7;36(5):1030-1043.e7. doi: 10.1016/j.cmet.2024.04.003. Epub 2024 Apr 25.
7
From Nonalcoholic Fatty Liver Disease to Metabolic Dysfunction-Associated Steatotic Liver Disease: Out with the Old, in with the New.从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病：旧去新来。
J Clin Med. 2024 Feb 2;13(3):880. doi: 10.3390/jcm13030880.
8
Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation.肠道微生物衍生的吲哚化合物通过改善脂肪代谢和炎症缓解代谢功能障碍相关的脂肪性肝病。
Gut Microbes. 2024 Jan-Dec;16(1):2307568. doi: 10.1080/19490976.2024.2307568. Epub 2024 Feb 1.
本文引用的文献
1
Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature.回复：关于新的脂肪性肝病命名的多学会德尔菲共识声明。
Hepatology. 2024 Mar 1;79(3):E93-E94. doi: 10.1097/HEP.0000000000000696. Epub 2023 Nov 20.
2
Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced modernity.代谢功能障碍相关脂肪性肝病的批判性评价：两面性现代性的启示。
Clin Mol Hepatol. 2023 Oct;29(4):831-843. doi: 10.3350/cmh.2023.0277. Epub 2023 Aug 25.
3
Community-centered Disease Severity Assessment of Metabolic Dysfunction-associated Fatty Liver Disease.以社区为中心的代谢功能障碍相关脂肪性肝病疾病严重程度评估
J Clin Transl Hepatol. 2023 Oct 28;11(5):1061-1068. doi: 10.14218/JCTH.2022.00103S. Epub 2023 May 24.
4
A new era for steatotic liver disease: Evaluating the novel nomenclature in the UK Biobank.脂肪性肝病的新时代：评估英国生物银行中的新命名法。
J Hepatol. 2024 Feb;80(2):e58-e60. doi: 10.1016/j.jhep.2023.07.007. Epub 2023 Jul 14.
5
Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B.肝脂肪变和代谢功能障碍对慢性乙型肝炎患者肝细胞癌风险的不同影响。
Hepatol Int. 2023 Oct;17(5):1139-1149. doi: 10.1007/s12072-023-10545-6. Epub 2023 May 29.
6
Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis.脂肪性肝病对慢性乙型肝炎长期结局的影响：一项系统评价和个体患者数据荟萃分析的匹配分析。
Clin Mol Hepatol. 2023 Jul;29(3):705-720. doi: 10.3350/cmh.2023.0004. Epub 2023 May 8.
7
Hepatic Outcomes of Nonalcoholic Fatty Liver Disease Including Cirrhosis and Hepatocellular Carcinoma.非酒精性脂肪性肝病包括肝硬化和肝细胞癌的肝脏结局。
Clin Liver Dis. 2023 May;27(2):211-223. doi: 10.1016/j.cld.2023.01.019. Epub 2023 Mar 9.
8
The relationship between metabolic dysfunction-associated fatty liver disease and the incidence rate of extrahepatic cancer.代谢相关脂肪性肝病与肝外恶性肿瘤发生率的关系。
Front Endocrinol (Lausanne). 2023 Feb 20;14:985858. doi: 10.3389/fendo.2023.985858. eCollection 2023.
9
The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.非酒精性脂肪性肝病（NAFLD）和非酒精性脂肪性肝炎（NASH）的全球流行病学：系统评价。
Hepatology. 2023 Apr 1;77(4):1335-1347. doi: 10.1097/HEP.0000000000000004. Epub 2023 Jan 3.
10
MAFLD: How is it different from NAFLD?MAFLD：与非酒精性脂肪性肝病（NAFLD）有何不同？
Clin Mol Hepatol. 2023 Feb;29(Suppl):S17-S31. doi: 10.3350/cmh.2022.0367. Epub 2022 Nov 29.
Zotero 插件